Ovarian cancer is complex, characterized by a high number of mutations (changes in DNA) in tumour cells, interactions between tumour and immune cells, and differences both within and between patients (e.g., over time or at different tumour sites). To date, ovarian cancer patients have shown a limited response to immune therapies; this indicates that further understanding of ovarian cancer genetics and interactions with the immune system is essential for developing more effective treatments.

Dr. Boudreau and her team aim to explore genetic and immunological factors contributing to ovarian cancer progression, relapse, and response to therapy in Nova Scotian patients.

In this project, the team will:

• Collect and analyze genetic data from different types of patient samples (e.g., blood, tumour, ascites) using sequencing techniques, to map how tumours change over time.
• Assess immune cell infiltration in tumour samples, focusing on the role of tumor-infiltrating lymphocytes and defining the features that are associated with good clinical outcomes.
• Use scientific techniques such as high-parameter immunohistochemistry, flow cytometry, and single-cell RNA sequencing to characterize immune cells and their interactions with tumours.
• Perform functional studies using patient-derived cell lines, xenograft models, and 3D culture systems to help identify immune targets and evaluate potential therapies.

This research aims to answer key questions about how genetic alterations predict relapse and treatment response, whether they affect immune cell infiltration, and how these insights can enable improved precision therapies for ovarian cancer. Furthermore, this project will generate valuable data to create a foundational research platform and database, supporting future research and potential novel interventions in ovarian cancer treatment.